SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as investors highlight its unique status as the original crypto parody project dating back to 2011, effectively blending long-standing internet lore with modern on-chain momentum. The community is buzzing over its historical significance and recent whale accumulation, framing the token as a persistent cultural movement that has outlasted years of market volatility.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with the community actively celebrating its early growth, developer accessibility, and airdrop events. Traders are focused on pushing the token past key market cap milestones while encouraging engagement through aggressive social media activity and strategic buying during dips.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing increased community chatter surrounding its role as a key liquidity hub on the Base ecosystem, with investors closely watching potential catalyst events and revenue growth. Community sentiment remains mixed, as some participants express frustration with current price action while others double down on accumulation strategies in anticipation of long-term utility gains.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with supporters highlighting organic growth, burned liquidity, and its inclusion on the Jupiter strict list. Investors are actively discussing its multi-year track record and utilizing meme-driven engagement to build momentum around the token's long-term potential.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility as community members react to high trading volume and speculative price action. Discussions are heavily focused on its role as a leading Solana DEX, with many participants debating potential price targets and sharing strategies for yield farming via liquidity pools.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is currently seeing intense speculative trading activity and elevated volume as investors price in hopes of a potential acquisition or partnership, specifically fueled by its ongoing relationship with Nestl. While the company continues to advance its microbiome-based pipeline, community discussion remains highly polarized between long-term holders awaiting a strategic liquidity event and traders looking to capitalize on rapid volatility and short-squeeze potential.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders actively accumulate during a consolidation phase, citing the project's unique "phygital" strategy and retail presence as key pillars for long-term growth. While some investors debate the risks of meme coin volatility, the community is heavily focused on potential breakout triggers and the project's ongoing brand expansion efforts.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

$TRUMP is experiencing intense volatility and community backlash as investors react to a high-profile Mar-a-Lago gala event for top token holders, which many participants are dismissing as a poorly timed distraction from the asset's significant decline. The community remains deeply divided, with vocal critics labeling the project a scam and pointing to its price performance, while a subset of supporters continues to speculate on potential recovery catalysts linked to broader political and market developments.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh an attractive valuation, high dividend yield, and consistent share buybacks against recent earnings headwinds and broader industry pressures. The community remains divided, with some betting on a long-term turnaround or potential acquisition, while others express frustration over the stock's sluggish price performance.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class B

Fox Corporation - Class B

Fox Corporation is currently drawing significant attention as community discussions intensify around the network's shifting political positioning and the impact of the departure of high-profile talent on viewership. Investors and viewers alike are debating the company's long-term media strategy amidst concerns over advertising revenue, shifting media consumption habits, and the stock's broader volatility within the entertainment sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences.</li><li>The firm believes Harmony’s Wakix franchise should be viewed as protected and fully intact through 2030.</li><li>Mizuho also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.</li></ul>Shares of Harmony Biosciences Holdings Inc. (HRMY) soared more than 18% in Tuesday’s midday trade after analysts at Mizuho announced that they have learned of a new patent lawsuit filed by the company.According to TheFly, Mizuho analysts stated that Harmony Biosciences has sued AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.<a href="https://stocktwits.com/symbol/HRMY">Harmony Biosciences shares</a> were up over 14% in Tuesday’s midday trade. Retail sentiment on Stocktwits about the company trended in ‘bullish’ territory, with message volume at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Is The Lawsuit About?</h2>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences. The lawsuit covers pitolisant, which was initially developed by Bioprojet and subsequently licensed exclusively by Harmony for the development, manufacture, and commercialization of pitolisant in the U.S.The firm now believes the Harmony Wakix franchise should be considered protected and fully intact through 2030. It also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.Mizuho contended that this lawsuit should also remove a major overhang on HRMY stock stemming from concerns that a generic version of pitolisant could be launched before 2030.The firm reiterated its ‘Outperform’ rating on Harmony, with a $50 price target, implying an upside of about 50% from current levels.Koyfin data shows that the average 12-month price target for Harmony is $42, implying an upside of about 27% from current levels. Of the 11 analysts covering the stock, six have either a ‘Strong Buy’ or a ‘Buy’ recommendation, four have a ‘Hold’ rating, and one has a ‘Strong Sell’ recommendation.<h2 class="st-heading-2">What Is Pitolisant Used For?</h2>Pitolisant, originally developed to treat excessive daytime sleepiness and cataplexy in narcolepsy patients, is also being evaluated by Harmony Biosciences for use in individuals with Prader-Willi syndrome.The company also has two pitolisant tablet formulations, namely Pitolisant GR and Pitolisant HD.Harmony is developing Pitolisant GR to enable treatment initiation within the therapeutic dose range. Pitolisant HD is a reformulated version designed to improve how the drug works in the body and to target additional symptoms, such as fatigue, in patients with narcolepsy.Harmony announced in February this year that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy.“With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy,” said Harmony Biosciences’ Chief Medical and Scientific Officer, Kumar Budur.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> is down 10% year-to-date, but up 18% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 43% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 51%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-soars-best-gains-4-months-what-is-fueling-rally/cZBI8d9RI6e">VELO Stock Soars 38%, Races Toward Best Single-Day Move In 4 Months — What Is Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say?

Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

Equity

A JetBlue Airways Airbus A321 airplane approaches San Diego International Airport for a landing from Boston on April 20, 2025 in San Diego, California. 

JetBlue CEO Vows Cash Pile Will Prevent Bankruptcy In 2026: Report 

Bloomberg reported on Monday, citing a memo to employees from CEO Joanna Geraghty, that the airline has sufficient liquidity and access to additional capital.

<ul class="summary-bullets"><li>The company said that it is announcing its preliminary net sales in advance as it expects to be interacting with investors and members of the ophthalmology community at an annual meeting in Washington DC later this week .</li><li>In the Middle East and some other parts of the EMEA and APAC regions, net sales were negatively affected by significant geopolitical and macroeconomic challenges.</li><li>STAAR also noted that it shipped minimal quantities of certain products to China during the quarter to manage the excess inventory with distributors and the inventory is now within targeted range.</li></ul>Shares of STAAR Surgical Company (STAA) rallied more than 19% after-hours on Wednesday after the company said that its first quarter (Q1) net sales are expected to exceed $90 million, ahead of Wall Street expectations of $67.59 million.The company reported net sales of $42.6 million for the corresponding quarter last year. &nbsp;STAAR Surgical said that it is announcing its preliminary net sales in advance, before its quarterly earnings, as it expects to be interacting with investors as well as members of the ophthalmology community at an annual meeting in Washington DC later this week.<h2 class="st-heading-2">Geographical Distinctions</h2>STAAR, which makes vision correction solutions that reduces or eliminates the need for glasses or contact lenses, said that it is pleased with its net sales in China, its largest market, for the quarter. China accounted for the majority of the increase in net sales, combined with double digit growth in the Americas, it said.However, in the Middle East and some other parts of the EMEA and APAC regions, net sales were negatively affected by significant geopolitical and macroeconomic challenges, resulting in a decline in sales in parts of those regions, the company said.The Lake Forest, California-headquartered company warned that sales growth could continue to be negatively affected in these regions. It also noted that it shipped minimal quantities of certain products to China during the quarter to manage the excess inventory with distributors and the inventory is now within targeted range.“Our higher net sales, combined with our significantly improved cost structure, are expected to drive a meaningful improvement in adjusted EBITDA (core profit) for the first quarter,” said Deborah Andrews, Interim Co-CEO.STAAR Surgical is expected to report its full first quarter earnings in early May. Wall Street on average expects adjusted core profit for the quarter to come in at $5.40 million.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around STAA stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. &nbsp;A Stocktwits user expressed hopes for some price target revisions after the announcement.<stembedurl>https://www.stocktwits.com/StockBraker/message/649769413</stembedurl>Another termed it a “turnaround moment.”<stembedurl>https://www.stocktwits.com/TheBullishTrade/message/649761840</stembedurl><a href="https://stocktwits.com/symbol/STAA">STAA stock</a> has gained 38% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-chinese-rival-beat-it-with-first-us-long-haul-electric-truck-delivery/cZJf7VDRIAA">Tesla’s Chinese Rival Beat It With First US Long Haul Electric Truck Delivery — What Does This Mean For The EV Giant?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Staar Surgical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did STAA Stock Surge More Than 19% After-Hours Today?

STAAR Surgical Company announced preliminary net sales for Q1, expected to exceed $90 million. 

<ul class="summary-bullets"><li>Matt Schultz, Chief Executive Officer and Chairman of CleanSpark, said that the company’s core Bitcoin mining operations provide cash flow to fund the company’s strategic investments.</li><li>This includes securing the company’s first hyperscale customer in AI and high-performance computing, while actively building out its talent pipeline.</li><li>The company continues to have 13,561 Bitcoin on its balance sheet.</li></ul>Shares of Bitcoin miner Cleanspark (CLSK) fell at market open on Wednesday after the company announced it had sold 70% of the Bitcoin (BTC) it mined in the month of March.<a href="https://stocktwits.com/symbol/CLSK/">CLSK’s stock</a> dropped more than 3% in morning trade amid&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/hedge-against-bitcoin-beats-btc-amid-crypto-market-dip/cZJJ8hPRIpf">broader weakness</a> in the crypto and equities markets. On Stocktwits, retail sentiment around the shares improved to ‘neutral’ from ‘bearish’ over the past day, while chatter dipped to ‘normal’ from ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_07_102644_png_c687b28843.webp" alt="Screenshot 2026-04-07 102644.png" width="1251" height="144"><figcaption>CLSK retail sentiment and message volume on April 7 as of 9:35 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">CleanSpark Sells 460 Bitcoin</h2>CleanSpark said it had holdings of 13,363 Bitcoin at the end of February and mined another 658 Bitcoin in March. However, at the end of the month the tally of Bitcoin on its balance sheet was at 13,561 BTC, instead of 14,021.&nbsp;The company sold 460 Bitcoin out of the 658 BTC it had mined over the course of the month at an average price of $71,396 for a total of $32.8 million. Most of the Bitcoin was sold at spot prices, while the rest was adjusted to address call and put exercises as well as other trading activities.&nbsp;Bitcoin’s price fell over 2% in the last 24 hours to around $67,900. Retail sentiment around the apex cryptocurrency on Stocktwits&nbsp;It added that it saw&nbsp;an operational hashrate of 50 Exahashes per second (EH/s) and an average operating hashrate of 47.3 EH/s over the past month. The company reported 1.8 gigawatts (GW) under contract with 808 megawatts (MW) currently utilized to support the fleet’s operational hashrate.<h2 class="st-heading-2">CleanSpark Sells Bitcoin To Fund AI-HPC Pivot</h2>CleanSpark is among the horde of Bitcoin miners, including Riot Platforms (RIOT), MARA Holdings (MARA),&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-supply-tugofwar-riot-mara-sell-strategy-buying/cZJJr55RIpj">selling the apex cryptocurrency</a> for some flexibility on their balance sheets to support their pivot towards artificial intelligence (AI) and high-performance computing (HPC) workloads."We continue to make significant headway toward securing our first hyperscale customer in AI and high-performance computing, while actively building out our talent pipeline to support these high-margin growth initiatives,” said Matt Schultz, Chief Executive Officer and Chairman of CleanSpark, adding that company’s core Bitcoin mining and digital asset management operations provide cash flow to fund the company’s strategic investments.In comparison, peers like Core Scientific (CORZ), Cipher Mining (CIFR) and MARA Holdings (MARA) have already&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mara-stock-is-rallying-today-what-is-all-the-buzz-about/cZTGrGCRIRW">announced</a> multi-year deals to host AI workloads.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/hedge-against-bitcoin-beats-btc-amid-crypto-market-dip/cZJJ8hPRIpf">‘Hedge Against Bitcoin’ Outperforms BTC Amid Crypto Market Dip On Record Shielded Supply</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of CleanSpark Inc.

CleanSpark Sold 70% Of The Bitcoin It Mined In March For Over $71,000 Apiece

Most of the Bitcoin was sold at spot prices, while the rest was adjusted to address call and put exercises as well as other trading activities. 

Cryptocurrency

Most of the Bitcoin was sold at spot prices, while the rest was adjusted to address call and put exercises as well as other trading activities. 


<ul class="summary-bullets"><li>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC&nbsp;reported, citing data from Argus.&nbsp;</li><li>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28.</li></ul>JetBlue Airways (JBLU) is reportedly raising bag fees for its flyers as rising fuel prices due to the ongoing Iran war begin to&nbsp;weigh on the company.“As we experience rising operating costs, we regularly evaluate how to manage those costs while keeping base fares competitive and continuing to invest in the experience our customers value,” JetBlue said in a statement to CNBC.Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC reported, citing data from Argus.&nbsp;Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28. The recent rise in checked bag fees is the latest indication that airlines are passing higher fuel costs onto American travelers. After labor, jet fuel is the largest expense for airlines.<h2 class="st-heading-2">Rising Fuel Prices&nbsp;</h2>Crude oil jumped on Monday and stayed well above $100 a barrel mark, signalling a prolonged Iran war.&nbsp;Benchmark U.S. oil futures gained $3.24 a barrel Monday to settle at $102.88, their first close above $100 since 2022 when Russia invaded Ukraine and rattled energy markets, as per Wall Street Journal.&nbsp; Brent crude futures for May delivery were as high as $116 Monday.&nbsp;The United States Oil Fund ETF (USO) closed 4.5% higher on Monday, while the ProShares Ultra Bloomberg Crude Oil ETF (UCO) ended the day 1.7% higher.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around JBLU&nbsp;stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen around 10% so far this year.&nbsp;

JetBlue Airbus A321neo passenger aircraft spotted departing from the runway of Amsterdam Schiphol Airport in the Netherlands on April 10, 2025.

JetBlue Airways Reportedly Raises Baggage Fees As Rising Fuel Costs Bite

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 

<ul class="summary-bullets"><li>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.</li><li>Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.</li><li>ADMA stock has declined nearly 29% since Culper’s short report was released on Tuesday.</li></ul>Adma Biologics Inc. (ADMA) has been downgraded by analysts at Cantor Fitzgerald, with the firm citing disappointment among investors following the company’s response to a short report.According to TheFly, Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">short report</a> on Tuesday.Cantor downgraded Adma Biologics to ‘Neutral’ from ‘Overweight’ without a price target. ADMA stock has declined nearly 29% since Culper’s short report was released.<a href="https://stocktwits.com/symbol/ADMA">Adma Biologics’ shares</a> were down more than 2% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">What Is Cantor Concerned About?</h2>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.According to Koyfin, the average 12-month price target for ADMA stock is $23.5, implying a return potential of 144% from current levels. Of the three analyst ratings, two have a ‘Buy’ recommendation, while one has a ‘Hold’ rating.<h2 class="st-heading-2">What Did The Short Report Flag?</h2>Culper Research stated in its short report that Adma Biologics’ sales growth is driven by a “de facto channel stuffing scheme.” The firm stated that Adma’s revenue declined 3% in 2025, after adjusting for sales inflation, while the company reported a 20% growth.The short seller also noted that the sales of Adma’s flagship product, Asceniv, have been inflated by 40% to 76%. “We believe the ASCENIV growth story is total fiction owing entirely to channel stuffing,” Culper added.The firm added that, based on its interactions with two high-level employees at one of Adma’s largest distributors, the biopharmaceutical company induced the distributor to stock excess Asceniv by offering rebates and extended payment terms to meet the distributor's order expectations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user on the platform stated that even if a part of Culper’s short report is true, it gives the company a black eye.<stembedurl>https://stocktwits.com/Tradeswithyourmom/message/648578343</stembedurl>However, a bullish user dismissed the short report, saying that there is nothing to see here.<stembedurl>https://stocktwits.com/glacier64/message/648588280</stembedurl><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> is down 47% year-to-date and 52% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 17% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-us-ceasefire-plan-maximalist-unreasonable-white-house-weekend-talks/cZ3YvQ5RISH">Iran Reportedly Says US Ceasefire Proposal Is 'Extremely Maximalist And Unreasonable' Even As White House Plans Weekend Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence

Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its short report on Tuesday.

<ul class="summary-bullets"><li>Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising."</li><li>The firm now awaits additional data in the second half of 2026 to better assess Sarepta's programs.</li></ul>Shares of Sarepta Therapeutics (SRPT) closed 35% higher on Wednesday despite Wall Street raising concerns on the company’s early clinical results for two of its programs in neuromuscular diseases.Leerink analyst Joseph Schwartz said the initial data released by the company earlier on Wednesday in genetic diseases myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy type 1 (FSHD1) are "a bit of a mixed bag." While it seems like they can achieve "impressive" muscle concentration, the DM1 data are "very limited and safety remains an open debate," said the analyst, who has a ‘Market Perform’ rating on Sarepta shares.Oppenheimer analyst Kostas Biliouris, meanwhile, said Sarepta's data in the programs "appear promising." However, the early nature of data and use of different sample sizes across measurements may bias the results, preventing conclusion, the analyst told investors in a research note. The firm awaits additional data in the second half of 2026 to better assess Sarepta's programs. The firm has an ‘Outperform’ rating on Sarepta with a $37 price target.<h2 class="st-heading-2">Sarepta’s Trial Data</h2>Sarepta said earlier in the day that early results from the studies of its investigational siRNA treatment SRP-1001 in FSHD1 and DM1 demonstrated dose- dependent muscle exposure, early biomarker effects, and favorable tolerability, which the company expects will lead to better clinical efficacy.Both DM1 and FSDH1 are genetic disorders caused by overexpression of mutant proteins or toxic mRNA and characterized by progressive muscle weakness. The experimental treatment is designed to reduce, or knock down, the production of DUX4 protein in skeletal muscle.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has dropped 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/terns-buyout-deal-ignites-optimism-for-enliven-therapeutics-blood-cancer-portfolio/cZ3Y6W6RIjP">Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Leerink analyst Joseph Schwartz said the initial data released by the company in genetic diseases DM1 and FSHD1 are "a bit of a mixed bag."

<ul class="summary-bullets"><li>DigitalOcean said that it intends to use the net proceeds from the offering to make investments in additional infrastructure capacity.</li><li>It also plans to further strengthen its balance sheet by paying down its existing Term Loan A, and use proceeds for general corporate purposes.</li><li>DigitalOcean is the Agentic Inference Cloud built for AI-native and Digital-native enterprises scaling production workloads.</li></ul>DigitalOcean (DOCN) shares plunged nearly 9% during extended hours of trading on Tuesday after it announced that it has commenced an underwritten public offering of $700 million of its shares.&nbsp;Additionally, DigitalOcean intends to grant the underwriters a 30-day option to purchase up to an additional $105 million of shares.The company in a statement said that the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.<h2 class="st-heading-2">Purpose To Use Proceeds</h2>DigitalOcean said that it intends to use the net proceeds from the offering to make investments in additional infrastructure capacity, beyond what it has previously communicated, to support customer demand for DigitalOcean’s cloud&nbsp;or AI platform.&nbsp;It also plans to further strengthen its balance sheet by paying down its existing Term Loan A, and use proceeds for general corporate purposes. DigitalOcean is in advanced discussions to secure this additional data center capacity to support its growth, it said.&nbsp;<h2 class="st-heading-2">What Is DigitalOcean</h2>DigitalOcean is the agentic inference cloud built for AI-native and digital-native enterprises scaling production workloads. The platform combines production-ready GPU infrastructure with a full-stack cloud to deliver operational simplicity and predictable economics at scale. The company has more than 640,000 customers.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around DOCN trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have jumped 75% year-to-date.&nbsp;&nbsp;

Shares of DigitalOcean have jumped 75% year-to-date. 

Why Is DigitalOcean Plunging Today?

DigitalOcean intends to grant the underwriters a 30-day option to purchase up to an additional $105 million of shares.

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.<h2 class="st-heading-2">Analyst Takeaway</h2>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.<h2 class="st-heading-2">About Vyondys And Amondys</h2>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.<h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Vanguard or iShares: Which Offers the Better Small-Cap ETF?

Key PointsVanguard Small-Cap ETF charges half the expense ratio of iShares Core S&P Small-Cap ETF, but both are extremely low-cost...

Current Price	$136.30
Prev Close	$135.57
Open	$136.22
Dividend Yield	N/A
50-Day Moving Average	$128.17
Beta	N/A
Avg. Volume	8.06M
PE Ratio	N/A

52-Week High	$137.29
52-Week Low	$98.21
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IJR
iShares Core S&P Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IJR News

IJRiShares Core S&P Small-Cap ETF